Corbus Pharmaceuticals Holdings, Inc. - 8-K Filing
Corbus Pharmaceuticals reported positive Phase 1b trial results for CRB-913, showing a mean weight loss of 5% at the highest dose with favorable safety and tolerability. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CRBP